Skip to main content
SpringerLink
Log in

Camrelizumab/pembrolizumab

Toxic epidermal necrolysis: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ruan Y, et al. Comment on "Toxic epidermal necrolysis during camrelizumab treatment for oesophageal squamous cell carcinoma". Contact Dermatitis 87: 387-388, No. 4, Oct 2022. Available from: URL: http://doi.org/10.1111/cod.14179

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Camrelizumab/pembrolizumab. Reactions Weekly 1926, 147 (2022). https://doi.org/10.1007/s40278-022-24425-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-24425-0

Search

Navigation